Evidence map›Paper›PMID 41778625›Full record

Trial reportFuture oncology (London, England)2026

Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial.

Shengnan Hao, Xiaomin Wang, Huiping Ding, Yun Chen, Qi Liu, Junhua Zhang, Xingwen Fan, Zhenhua Wu, Ying Lin, Xiaofang Xu and 15 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06787313 (Precision Palliative Care for Patients With Advanced Esophageal Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06787313 recruitingnot on this map

Precision Palliative Care for Patients With Advanced Esophageal Cancer: a Randomized Phase III Trial

TypeobservationalSponsorFudan UniversityRan2024 to 2028Enrolled624ConditionsEsophageal CancerArmsprecision palliative care
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Shengnan HaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaomin WangDepartment of Radiation Oncology, Anyang Tumor Hospital, Anyang City, Henan Province , China.
Huiping DingDepartment of Clinical Nutrition, Fudan University Shanghai Cancer Center, Shanghai, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Junhua ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xingwen FanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhenhua WuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ying LinDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaofang XuDepartment of Oncology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Guangmin MaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dashan AiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaying DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongcheng ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jinjun YeDepartment of Endoscopy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
Miao MoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhihuang HuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Huijie WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wenwu ChengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wei FengDepartment of Psychological Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Yiqun LingDepartment of Clinical Nutrition, Fudan University Shanghai Cancer Center, Shanghai, China.
Yufen XuDepartment of Oncology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Shisuo DuDepartment of Radiation Oncology, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Jialei WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over half of patients with advanced or recurrent esophageal cancer experience malnutrition, psychological distress, and cancer-related pain, which impair immune function, diminish quality of life, and attenuate responses to immunotherapy. Whether a precision palliative care (PC) model that integrates nutritional, psychological, and symptomatic support can improve survival and quality of life in these patients undergoing anti-PD-1/PD-L1 immunotherapy remains unknown. We are conducting a multicenter randomized trial to evaluate the superiority of a precision PC model compared with standard oncology care in improving patients' overall survival (OS). All patients will be randomly assigned to either the Standard Arm (standard oncology care)or the Precision Arm (standard oncology care + precision PC). Patients in the Standard Arm receive anti-PD-1/PD-L1 immunotherapy-based standard oncology care. Patients assigned to the Precision Arm receive anti-PD-1/PD-L1 immunotherapy-based standard oncologic care and precision PC, in which patients meeting any of the following criteria are stepped up to meet with the precision PC clinicians every 4 weeks: (1) malnutrition (NRS2002 ≥ 3 or meeting GLIM criteria), (2) psychological distress (GAD-7 ≥ 5 or PHQ-9 ≥ 5), or (3) moderate-to-severe symptoms (any MDASI symptom score ≥4). The primary endpoint is overall survival (OS). The secondary endpoints are quality of life and progression-free survival (PFS).Clinical trial registration: NCT06787313 (clinicaltrials.gov).

Indexed as

Esophageal NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalPalliative CarePrecision MedicineAdultB7-H1 AntigenFemaleHumansImmunotherapyMaleMiddle AgedProgrammed Cell Death 1 ReceptorQuality of LifeB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptoradvanced/recurrent canceranti-PD-1/PD-L1 immunotherapyEsophageal cancerinterdisciplinary precision palliative carestandard oncology care

Identifiers

PMID41778625
PMCPMC12977270

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.